Clinical Trials Logo

Filter by:
NCT ID: NCT04261777 Recruiting - Prostate Cancer Clinical Trials

Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

Start date: May 27, 2020
Phase: Phase 3
Study type: Interventional

This will be a confirmatory, prospective, open-label, single-arm, reader-blinded, multi-centre phase 3 study to assess the diagnostic accuracy and safety of Ferrotran®-enhanced MRI in comparison to unenhanced MRI in the detection of pelvic lymph node metastases in newly-diagnosed adult patients with prostate cancer and an intermediate to high risk for lymph node metastases, based on the D'Amico criteria.

NCT ID: NCT04260789 Recruiting - Clinical trials for Bloodstream Infection

Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection

Start date: August 19, 2020
Phase: N/A
Study type: Interventional

Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the reduction of pathogen load from the blood in septic patients with suspected, life-threatening bloodstream infection

NCT ID: NCT04259567 Recruiting - Septic Shock Clinical Trials

Improvement of Cerebrovascular Autoregulation in Patients With Septic Shock Due to Cytokine Elimination

SepsAR3
Start date: June 8, 2020
Phase: N/A
Study type: Interventional

The trial investigates the effect of cytokine elimination in patients with septic schock and acute renal failure with need for renal replacement therapy on the integrity of cerebrovascular autoregulation. Patients with inclusion criteria were randomly assign in either use of CytoSorb filter integrated in renal replacement therapy versus non additional filter an renal replacement therapy alone. Cerebrovascular autoregulation will be measured with transcranial Doppler ultrasound and correlation with arterial blood pressure.

NCT ID: NCT04257630 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Coping Strategies Within Pulmonary Rehabilitation in Patients With IPF and COPD

Start date: February 6, 2020
Phase:
Study type: Observational

The aim of this prospective observational trial is to evaluate the influence of Coping strategies on pulmonary rehabilitation outcomes like 6-minute walk distance and Quality of life.

NCT ID: NCT04257292 Recruiting - Clinical trials for Infective Endocarditis

NExt-Generation Sequencing and Cell Culture-based Characterization of S. Aureus in Infective Endocarditis

NESSIE
Start date: September 1, 2019
Phase:
Study type: Observational

Infective endocarditis is a deadly disease with a mortality rate between 20 and 40%. Antibiotic therapy is of utmost importance. It is primarily guided by microbial results from positive blood culture. However, culture-based microbiological diagnostic can identify the species, but not the strain or the genotypic characteristics of a pathogen. Identifying the strain can be of utmost clinical significance. S. aureus is the most common causative organism of IE worldwide (16%-32%). This pathogen causes massive valve destruction and abscesses, which is strongly dependent on the expression of virulence factors that vary between different S. aureus strains. Functional characterization of S. aureus and determination of virulence factors can currently be achieved through cell culture-based assays (CCBA). However, these tests are very time consuming and cannot be performed as routine clinical diagnostics. Next Generation Sequencing (NSG) has the potential to identify the genotypic characteristics of the pathogen, which is important to determine its virulent potential. The aim of this study is to evaluate the possible utilization of NGS in the prediction of virulence factors of S. aureus and to compare it to the virulence factors determined using CCBA. Hopefully, by comparing the NGS and CCBA, the investigators will get a faster way of determining the possible virulence factors. The NGS method can be further utilized to describe the prevalence of different strains of bacteria in infected valve tissue and blood culture samples. The collected data will serve as a basis for further evaluation of the potentials of NGS-based Diagnosis of IE, as well as a comparison between NGS-guided antibiotic treatment and the standard of care antibiotic treatment.

NCT ID: NCT04253015 Recruiting - Neuroblastoma Clinical Trials

A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

Start date: September 30, 2019
Phase:
Study type: Observational [Patient Registry]

This is a non-interventional, multi-national, observational, prospective patient registry to further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal immunoglobulin G 1 (IgG1) antibody, to obtain information on survival, pain severity and incidence of neuro-toxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.

NCT ID: NCT04251780 Recruiting - Clinical trials for Primary Hyperaldosteronism

Tissue K+ in Primary Hyperaldosteronism

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Recent human studies found tissue sodium storage in patients with hyperaldosteronism that could be detected non-invasively by 23Na-MRI. Tissue sodium accumulation could be mobilized upon treatment of hyperaldosteronism. Besides, former animal studies applying chemical electrolyte analysis indicate that this aldosterone induced sodium storage might be accompanied by intracellular potassium loss. Wether such an intracellular tissue Potassium loss occurs in vivo in patients with hyperaldosteronism and if this deficiency can be corrected by treatment is unclear. The investigators will employ 39K-MR Imaging at 7Tesla to further assess this hypothesis.

NCT ID: NCT04251143 Recruiting - Keratoconus Clinical Trials

Dresden Corneal Disease and Treatment Study

Start date: March 12, 2018
Phase:
Study type: Observational

The purpose of this study is long-term follow up of patients with corneal diseases to analyze the quality of surgical interventions and diagnosis. Corneal ectasia, especially keratoconus, is a corneal disease that leads to an irreversible loss of visual acuity while the cornea becomes steeper, thinner and irregular. For these patients, surgical intervention (e.g. corneal cross-linking) is performed, in case of disease progression. Overall, a long-term follow up is needed to evaluate an early disease progression as well as corneal stability after surgical intervention.

NCT ID: NCT04247256 Recruiting - Clinical trials for Metastatic Colorectal Cancer

A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

Start date: May 14, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the combination of SCO-101 to FOLFIRI for the treatment of metastatic colorectal cancer patients who have developed resistance to FOLFIRI treatment. The study is divided in two parts, where the first part evaluates the safety and toxicity of increasing doses of SCO-101 in combination with FOLFIRI at the same dose as the patient has previously developed resistance to. The second part of the study evaluates the safety and efficacy of the combination of FOLFIRI and SCO-101 at the dose level established in the first part.

NCT ID: NCT04246463 Recruiting - Surgery Clinical Trials

Terumo Aortic Global Endovascular Registry

TiGER
Start date: December 17, 2019
Phase:
Study type: Observational

Multi-arm, multi-center, open label, prospective observational registry designed to obtain safety and performance data on the use of CE marked and custom Terumo Aortic endovascular grafts.